Promazine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page

Promazine

Phenothiazines With Aliphatic Side-Chain

GB MHRA

Drug class: Phenothiazines With Aliphatic Side-Chain
Availability: See label
Markets covered: 1
Products on record: 8

N05AAPhenothiazines With Aliphatic Side-Chain

Overview

Promazine is an active pharmaceutical ingredient in the Phenothiazines With Aliphatic Side-Chain group (N05AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	8	May 22, 2026

GBUnited Kingdom· MHRA

8 products

Uses

GBOfficial regulatory label· revised July 4, 2025[1]

As an adjunct to non-pharmacological interventions in the short-term management of moderate to severe agitation and restlessness where there is a risk of harm to the individual or to others.

How to take

Drug interactions

Known interactions involving Promazine. Select one for details. This list is informational and not a complete interaction checker.

Alfentanil Amiodarone Amisulpride Anagrelide Arsenic Trioxide Bedaquiline Benzhydrocodone Buprenorphine Bupropion Butorphanol Cabozantinib Ceritinib Chloroquine Citalopram Clozapine Codeine Crizotinib Deutetrabenazine Dihydrocodeine Disopyramide Dofetilide Dolasetron Dronedarone Droperidol Efavirenz Escitalopram Fentanyl Fingolimod Gatifloxacin Haloperidol Hydrocodone Hydromorphone Hydroxychloroquine Ibutilide Iloperidone Iohexol Iopamidol Ivabradine Ivosidenib Lefamulin Levorphanol Lumefantrine Macimorelin Meperidine Mesoridazine Methadone Metoclopramide Mifepristone Morphine Moxifloxacin Nalbuphine Nilotinib Oliceridine Osimertinib Oxycodone Oxymorphone Ozanimod Panobinostat Pasireotide Pentazocine Pimozide Potassium Chloride Potassium Citrate Procainamide Propoxyphene Quinidine Remifentanil Ribociclib Saquinavir Selpercatinib Siponimod Sotalol Sufentanil Tapentadol Tetrabenazine Thioridazine Topiramate Toremifene Tramadol Vandetanib Vemurafenib Ziprasidone Zonisamide Abiraterone Acarbose Acebutolol Acetazolamide Acetylcholine Aclidinium Acrivastine Activated Charcoal Adenosine Albiglutide Albuterol Aldesleukin Alfuzosin Alogliptin Alprazolam Amantadine Amifampridine Amiloride Aminolevulinic Acid Amitriptyline Amlodipine Amobarbital Amoxapine Amphetamine Amphotericin B Amyl Nitrite Apalutamide Apomorphine Apraclonidine Arformoterol Aripiprazole Asenapine Atenolol Atomoxetine Atropine Azelastine Azilsartan Azithromycin Baclofen Benazepril Benzphetamine Betaxolol Bicalutamide Biperiden Bisacodyl Bisoprolol Botulinum Toxin Type A Botulinum Toxin Type B Brexanolone Brexpiprazole Brimonidine Brivaracetam Bromocriptine Brompheniramine Bumetanide Buspirone Butabarbital Butalbital Cabergoline Canagliflozin Cannabidiol Capreomycin Captopril Carbamazepine Carbamoylcholine Carbinoxamine Cariprazine Carisoprodol Carvedilol Castor Oil Celecoxib Cenobamate Cetirizine Chlordiazepoxide Chlorothiazide Chlorpheniramine Chlorpromazine Chlorpropamide Chlorthalidone Chlorzoxazone Cilostazol Cinacalcet Ciprofloxacin Cisplatin Clarithromycin Clemastine Clevidipine Clidinium Clobazam Clofazimine Clomipramine Clonazepam Clonidine Clorazepate Cosyntropin Cyclobenzaprine Cyproheptadine Dantrolene Dapagliflozin Darifenacin Dasatinib Daunorubicin Degarelix Desipramine Desvenlafaxine Dexbrompheniramine Dexmedetomidine Dexmethylphenidate Dextroamphetamine Dextromethorphan Diazepam Diazoxide Dichloralphenazone Dicyclomine Diethylpropion Diltiazem Dimenhydrinate Diphenhydramine Donepezil Dopamine Doxazosin Doxepin Doxorubicin Doxylamine Dronabinol Dulaglutide Duloxetine Eluxadoline Empagliflozin Enalapril Encorafenib Entacapone Entrectinib Enzalutamide Ephedrine Epinephrine Epirubicin Eplerenone Eprosartan Eribulin Ertugliflozin Erythromycin Esketamine Eslicarbazepine Esmolol Estazolam Eszopiclone Ethacrynate Ethanol Ethosuximide Ethotoin Exenatide Ezogabine Famotidine Felbamate Felodipine Fenoldopam

Showing 240 of 538. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL004275014 · revised July 4, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised July 4, 2025[1]

Promazine is a member of the phenothiazine group of drugs and the size effects associated with that group have been noted. System Organ Class Blood and lymphatic system disorders Sensitivity reactions including agranulocytosis, leucopenia, haemolytic anaemia.
Psychiatric disorders Apathy, confusional state. Some individuals may be susceptible to the drug in low dosage and show paradoxical effects of excitement, agitation or insomnia and other minor side effects. 4). Nervous system disorders Drowsiness, dizziness, headache, sedation, epileptic fits, extrapyramidal symptoms (dystonia, tremor, tardive dyskinesia and akathisia), neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction altered consciousness) may occur with any neuroleptic.
Eye disorders Blurred vision, precipitation of glaucoma, corneal and lens opacities and purplish pigmentation of the skin, cornea, conjunctiva and retina. Cardiac disorders Tachycardia, cardiovascular effects include hypotension. Phenothiazines can produce ECG changes with prolongation of QT interval and T-wave changes, ventricular arrhythmias (VF, VT (rare)), sudden unexplained death, cardiac arrest and Torsades de pointes have been reported.
Respiratory, thoracic and mediastinal disorders Nasal stuffiness Gastrointestinal disorders Gastrointestinal disturbances, dry mouth, constipation. Hepatobiliary disorders Transient abnormalities of liver function tests may occur without jaundice.
Rarely - obstructive jaundice associated with stasis in biliary canaliculi. Treatment should then be withdrawn and not given again. Skin and subcutaneous tissue disorder Sensitivity reactions including allergic skin reactions, rashes, photosensitisation and contact sensitization.
Renal and urinary disorders Urinary hesitancy or retention when due to enlarged prostate. Reproductive system and breast disorders Menstrual disturbances, galactorrhoea, gynaecomastia, impotence. General disorders and administration site conditions Hypothermia, hyperpyrexia.
6). Investigations Weight gain The elderly are particularly susceptible to side effects of Promazine, especially to the sedative, hypotensive and temperature regulation effects. This may be dose related. Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs – Frequency unknown Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised July 4, 2025[1]

1. Acute withdrawal symptoms, including nausea, vomiting, sweating and insomnia have been described after abrupt cessation of antipsychotic drugs. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported.
Therefore, gradual withdrawal is advisable. 2. Phenothiazine should only be used with great caution in patients with a history of jaundice or with existent liver dysfunction, or blood dyscrasias, (perform blood counts if unexplained infection or fever occurs) coronary insufficiency or cardiac disease.
3. Respiratory depression may occur in patients with severe respiratory disease. 4. Promazine should be used with caution in patients with renal failure. 5. Patients receiving phenothiazines over a prolonged period require regular and careful surveillance with particular attention to potential for inducing eye changes (corneal and lens opacities and purplish pigmentation of the skin, cornea, conjunctiva and retina), effects on haemopoiesis, liver dysfunction, myocardial conduction effects, particularly if other concurrently administered drugs also have potential effects on these systems.
6. Use of phenothiazines at high (relative or absolute) doses may induce extrapyramidal side effects, dyskinesia, akathisia, dystonia. These are likely to be particularly severe in children. Caution should be exercised in patients with Parkinson’s disease.
Anti-parkinson agents should not be prescribed routinely because of the risk of aggravating anticholinergic side effects of Promazine, of precipitating toxic-confusional states or of impairing its therapeutic efficacy. They should be given only as required.
7. Prolonged administration of phenothiazines may result in persistent or tardive dyskinesias particularly in the elderly. The risk of tardive dyskinesia and the likelihood of irreversibility are believed to increase as the duration of therapy and total cumulative dose increase.
Neuroleptic therapy should be withdrawn if dyskinesia develops. 8. Care should be exercised if Promazine is used for the treatment of patients with cerebral arteriosclerosis, coronary heart disease or other conditions in which a fall in blood pressure might be undesirable.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations